1-甲基-6-(2-硝基苯基)吡唑并[3,4-d][1,3]恶嗪-4-酮 | 138187-95-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-甲基-6-(2-硝基苯基)吡唑并[3,4-d][1,3]恶嗪-4-酮
• 英文名称: 1-methyl-6-(2-nitrophenyl)-pyrazolo<3,4-d>-1,3-oxazin-4(1H)-one
• 英文别名: 1-methyl-6-(2-nitrophenyl)-pyrazolo[3,4-d]-1,3-oxazin-4(1H)-one；Pyrazolo(3,4-d)(1,3)oxazin-4(1H)-one, 1-methyl-6-(2-nitrophenyl)-；1-methyl-6-(2-nitrophenyl)pyrazolo[3,4-d][1,3]oxazin-4-one
• CAS: 138187-95-8
• 化学式: C₁₂H₈N₄O₄
• 分子量: 272.22
• InChiKey: AOLKIVFNDSWHTA-UHFFFAOYSA-N

物化性质

• 沸点：
  465.9±28.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-甲基-6-(2-硝基苯基)吡唑并[3,4-d][1,3]恶嗪-4-酮 在 一水合肼 作用下， 生成
  参考文献：
  名称：

  吡唑并[3,4-d]嘧啶衍生物作为COX-2选择性抑制剂：合成和分子建模研究

  摘要：

  吡唑并[3,4-d]嘧啶系统显示出许多有趣的药理特性。由于 5-苯甲酰胺基-吡唑并[3,4-d]嘧啶-4-one衍生物具有潜在的抗炎活性，并考虑到这类化合物的合成容易，研究人员开发了一套新的5-苯甲酰胺基-1H-吡唑并[3,4-d]嘧啶-4-one衍生物。通过 5-氨基吡唑-4(N-苯甲酰基)碳酰肼衍生物和合适的原三乙酯反应，3,4-d]嘧啶-4-酮的产率为42-80%。与参考标准 NS398 和吲哚美辛相比，化合物 8a、b、10a-d 和 11a、b 显示出对 COX-2 的优异抑制特性。分子模型研究证实了所获得的生物学结果。

  DOI：

  10.1002/ardp.200800140
• 作为产物：
  描述：

  5-氨基-1-甲基吡唑-4-甲酸乙酯 在 吡啶 、 Br₂C₂Cl₄ 、 一水合肼 、 三乙胺 、 三苯基膦 作用下， 以 1,4-二氧六环 、 异丙醇 、 甲苯 为溶剂， 反应 36.5h， 生成 1-甲基-6-(2-硝基苯基)吡唑并[3,4-d][1,3]恶嗪-4-酮
  参考文献：
  名称：

  Inhibitors of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel 2-aryl substituted pyrido[3,4-d][1,3]-, pyrido[2,3-d][1,3]-, pyrazino[2,3-d][1,3]-, pyrimido[4,5-d][1,3]-, pyrazolo[3,4-d][1,3]-, thieno[3,2-d][1,3]- and thieno[2,3-d][1,3]-oxazin-4-ones

  摘要：

  The synthesis of a series of 2-aryl substituted hetero annulated 1,3-oxazin-4-ones and their evaluation as specific inhibitors of the tissue factor (TF)/factor VIIa (FVIIa)-induced pathway of coagulation is reported. Inhibitory activities (IC50 values) in the range 0.64 to > 40 muM on the activation of factor X (FX) by the TF/FVIIa complex were found for compounds having one or two electronegative substituents such as F and NO2 in the 2-aryl substituent. Some of the compounds showed a selectivity ratio towards FX and thrombin of > 50, thus being similar in specificity to 2-aryl substituted 4H-3,1-benzoxazin-4-ones described as potential drugs for oral antithrombotic treatment without side effects, such as bleeding, which is observed especially with thrombin inhibitors. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00207-8

文献信息

• Daidone; Bajardi; Roccaro, Il Farmaco, 1991, vol. 46, # 7-8, p. 945 - 957
  作者：Daidone、Bajardi、Roccaro、Raffa、Caruso、Cutuli、Di Pietro

  DOI：——

  日期：——
• Use of heterocyclic compounds as scce inhibitors
  申请人：Linschoten Marcel

  公开号：US20060258651A1

  公开（公告）日：2006-11-16

  The present invention relates to heterocyclic inhibitors of stratum corneum chymotryptic enzyme (SCCE). More particularly, the invention relates to the use of compounds with the formula (I) or (II) for treatment of certain diseases, in particular skin diseases such as pruirtus, as well as cancer such as ovarian cancer.
• US7872052B2
  申请人：——

  公开号：US7872052B2

  公开（公告）日：2011-01-18
• [EN] HETEROCYCLIC COMPOUNDS REGULATING CLOTTING<br/>[FR] COMPOSES HETEROCYCLIQUES REGULANT LA COAGULATION
  申请人：NOVO NORDISK AS

  公开号：WO2000030646A1

  公开（公告）日：2000-06-02

  The invention relates to the use of heterocyclic compounds with formulas (I) and (II), and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for treatment of coagulation-related diseases. The compounds are inhibitors of TF-FVIIa activity and thus show anticoagulant activity. The invention also relates to methods of treatment. The invention furthermore relates to novel compounds with the formula (I) or (II).
• Inhibitors of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel 2-aryl substituted pyrido[3,4-d][1,3]-, pyrido[2,3-d][1,3]-, pyrazino[2,3-d][1,3]-, pyrimido[4,5-d][1,3]-, pyrazolo[3,4-d][1,3]-, thieno[3,2-d][1,3]- and thieno[2,3-d][1,3]-oxazin-4-ones
  作者：Palle Jakobsen、Anne Marie Horneman、Egon Persson

  DOI：10.1016/s0968-0896(00)00207-8

  日期：2000.12

  The synthesis of a series of 2-aryl substituted hetero annulated 1,3-oxazin-4-ones and their evaluation as specific inhibitors of the tissue factor (TF)/factor VIIa (FVIIa)-induced pathway of coagulation is reported. Inhibitory activities (IC50 values) in the range 0.64 to > 40 muM on the activation of factor X (FX) by the TF/FVIIa complex were found for compounds having one or two electronegative substituents such as F and NO2 in the 2-aryl substituent. Some of the compounds showed a selectivity ratio towards FX and thrombin of > 50, thus being similar in specificity to 2-aryl substituted 4H-3,1-benzoxazin-4-ones described as potential drugs for oral antithrombotic treatment without side effects, such as bleeding, which is observed especially with thrombin inhibitors. (C) 2000 Elsevier Science Ltd. All rights reserved.